AstraZeneca to acquire Amolyt Pharma,
expanding late-stage rare disease pipeline
PUBLISHED14 March 2024
Amolyt development portfolio includes Phase III asset with potential to address
significant unmet need in patients with chronic hypoparathyroidism
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond
complement inhibition, building on company’s success in bone metabolism and
opportunity in rare endocrinology
https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html
- Forums
- ASX - By Stock
- NEU
- Merck to acquire Prometheus in a US$ 10.8 b deal
Merck to acquire Prometheus in a US$ 10.8 b deal, page-108
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.09 |
Change
-0.220(1.14%) |
Mkt cap ! $2.437B |
Open | High | Low | Value | Volume |
$19.14 | $19.14 | $18.50 | $7.048M | 371.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 420 | $19.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.09 | 1 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 630 | 18.950 |
1 | 27 | 18.900 |
1 | 132 | 18.850 |
1 | 170 | 18.810 |
1 | 50 | 18.710 |
Price($) | Vol. | No. |
---|---|---|
19.110 | 225 | 1 |
19.200 | 20 | 1 |
19.240 | 1000 | 1 |
19.490 | 2000 | 1 |
19.500 | 1000 | 1 |
Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
Last
$19.03 |
  |
Change
-0.220 ( 0.79 %) |
|||
Open | High | Low | Volume | ||
$18.96 | $19.10 | $18.52 | 96070 | ||
Last updated 15.59pm 10/05/2024 ? |
Featured News
NEU (ASX) Chart |